Gujarat Themis Biosyn Limited (GTBL) has reported a significant increase in its financial performance for the second quarter, alongside a major expansion in its manufacturing capabilities.

Financial Highlights

The company's Q2 financial results show robust growth in profitability:

GTBL's performance demonstrates strong improvement in both top-line growth and profitability.

Operational Expansion

In a significant development, GTBL has completed the expansion of its Fermentation Block at its manufacturing facilities in Vapi, Gujarat. Key points of this expansion include:

• Commercial production of Rifamycin-S and Rifamycin-O commenced on October 18, 2025.
• The overall fermentation capacity has increased from 450 KL to 990 KL, more than doubling the previous capacity.
• This expansion strengthens GTBL's capabilities to produce multiple fermentation products.

Board Appointment

GTBL has appointed Mr. Rajneesh Anand as Additional Non-Executive Non-Independent Director for a five-year term effective November 10, 2025. Mr. Anand brings valuable experience to the board:

• He is a mechanical engineering graduate with management qualifications.
• Has been associated with Themis Group since 1977.
• Currently serves as Director of Themis Medicare Limited.

Outlook

With the expanded fermentation capacity and improved financial performance, Gujarat Themis Biosyn appears well-positioned in the bulk drugs manufacturing sector. The company's focus on enhancing its production capabilities aligns with the demand for pharmaceutical ingredients.

Gujarat Themis Biosyn Limited (GTBL) has marked a significant milestone in its growth trajectory with the commencement of commercial production at its expanded Fermentation Block in Vapi, Gujarat. The company officially began production of Rifamycin-S and Rifamycin-O on October 18, 2025, signaling a substantial boost to its manufacturing capabilities.

Capacity Expansion Details

The expansion project has more than doubled GTBL's fermentation capacity, as detailed in the following table:

This significant increase in capacity positions GTBL to capitalize on growth opportunities within the fermentation segment, particularly in the production of multiple fermentation products.

Strategic Implications

The expansion of the Fermentation Block at Vapi carries several strategic implications for GTBL:

1. Enhanced Production Capabilities: The more than doubled capacity allows GTBL to significantly increase its output of fermentation products.
2. Product Diversification: The expanded facilities enable the company to produce a wider range of fermentation products, potentially opening new market opportunities.
3. Market Position: With increased capacity, GTBL is better positioned to meet growing market demand and potentially increase its market share in the fermentation segment.
4. Operational Efficiency: The new facilities may lead to improved operational efficiencies and economies of scale.

Company's Statement

In its official communication to the stock exchanges, GTBL stated, "With this capacity expansion, the Company is in a strong position to capitalise on the significant growth opportunities in the fermentation segment."

The commencement of commercial production at the expanded facility marks a pivotal moment for Gujarat Themis Biosyn Limited. As the company leverages its enhanced manufacturing capabilities, stakeholders will be keenly watching how this translates into business growth and market performance in the coming quarters.